Scalable solutions to common global ATMP bottlenecks through coordinated national collaboration.
A unified national infrastructure makes ATMP development in Norway easier to navigate, easier to partner with, and more scalable for the future.
Reduce duplication across the Norwegian ATMP ecosystem.
Control cost and improve development efficiency.
Shorten timelines to first-in-human studies.
Enable equitable access to innovation across the country.
Strengthen collaboration between academia, healthcare, and industry.
Cell and gene therapies hold the potential to cure diseases that currently lack effective treatments. However, translating these therapies from discovery to clinical use involves high technical and regulatory complexity, significant costs, and reimbursement challenges that can delay or prevent patients from accessing innovation.
A national gap analysis conducted in 2023 revealed that Norway lacked the infrastructure, strategy, and capabilities needed to develop and deliver advanced therapies at a national level.
Unequal access to innovation across the country.
Limited pre-GMP capacity outside Oslo.
No coordinated national ATMP strategy.
No national GMP-grade quality control service.
Delayed translation, higher costs, and weaker national preparedness.
Founded in 2025 as a joint initiative of Oslo University Hospital and Haukeland University Hospital, ATMP Norway operates as a multi-nodal national infrastructure spanning Oslo and Bergen.
It aligns infrastructure, expertise, governance, and public-private collaboration across the full development value chain — from discovery and pre-GMP process development through GMP manufacturing, quality control, training, and regulatory support, all the way to patient access.
ATMP Norway is jointly established and governed by two university hospitals, combining their clinical expertise, manufacturing facilities, and research capabilities into a single national infrastructure.
Norway's largest hospital and a leading centre for advanced medical research. Home to the Norwegian Radium Hospital and Rikshospitalet nodes, providing pre-GMP development, GMP manufacturing, and national quality control capabilities.
Western Norway's largest hospital and a key partner in the national ATMP infrastructure. Hosts a pre-GMP process development node and a GMP manufacturing node, extending national capacity beyond the capital.
ATMP Norway is governed through an Executive Management Board and a Steering Committee.
The Steering Committee is constituted by leadership representatives from the three partner institutions
The Executive Management Board is constituted by head of nodes, the ATMP management, and OUS
Top photo: Øystein Fykse / Helse Bergen